US Broker Ratings

uniQure N.V. (QURE) Stock Analysis: Exploring a 137% Potential Upside in Biotechnology

uniQure N.V. (NASDAQ: QURE), a pioneering player in the biotechnology sector, stands at an intriguing juncture with its current market dynamics and future potential. With a..

Avadel Pharmaceuticals plc (AVDL) Stock Analysis: A Promising 90.41% Potential Upside in the Healthcare Sector

Avadel Pharmaceuticals plc (NASDAQ: AVDL) stands out in the healthcare sector as an intriguing investment opportunity for those looking to capitalize on the biopharmaceutical market. This..

Xeris Biopharma Holdings, Inc. (XERS) Investor Outlook: Unpacking the 21% Potential Upside

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) has emerged as a notable player in the healthcare sector, specifically within the biotechnology industry. With a market capitalization of..

Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring a Remarkable 244% Potential Upside

Vir Biotechnology, Inc. (NASDAQ: VIR) stands as a compelling investment opportunity within the biopharmaceutical sector, showcasing a remarkable potential upside of 244.41%. With a focus on..

Arbutus Biopharma (ABUS) Stock Analysis: Exploring a Potential 54% Upside in the Biotech Sector

Arbutus Biopharma Corporation (NASDAQ: ABUS), headquartered in Warminster, Pennsylvania, is making waves in the healthcare sector with its innovative approach to treating infectious diseases. Specializing in..

Immunome, Inc. (IMNM) Stock Analysis: A Biotech Play with 173.74% Potential Upside

Investors with a keen eye on the biotechnology sector might find Immunome, Inc. (NASDAQ: IMNM) an intriguing prospect. With a market capitalization of $778.76 million, this..

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Unveiling a Substantial 187.96% Upside Potential in Biotechnology

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a rising star in the biotechnology sector, offers investors an intriguing opportunity with its clinical-stage therapeutics targeting severe autoimmune and inflammatory..

AnaptysBio, Inc. (ANAB) Stock Analysis: Investors Eyeing 82% Upside on Promising Biotech Innovations

AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology firm based in San Diego, California, is capturing investor attention with its innovative immunology therapeutics and a promising stock potential...

Beta Bionics, Inc. (BBNX) Stock Analysis: Exploring a 51% Potential Upside in the Medical Devices Sector

Beta Bionics, Inc. (NASDAQ: BBNX) is capturing investor interest with its promising potential upside of 51.37%, according to analyst ratings. Operating in the dynamic healthcare sector,..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: A Biotech Gem with 51% Potential Upside

LENZ Therapeutics, Inc. (NASDAQ: LENZ) is gaining attention in the biotechnology sector with its promising pipeline and impressive potential upside. As a company dedicated to improving..

Day One Biopharmaceuticals (DAWN) Stock Analysis: A 332% Potential Upside Opportunity in Biotech

Day One Biopharmaceuticals, Inc. (DAWN) is gaining attention in the biotech sector, with a compelling investment narrative supported by an impressive potential upside of 332.10%. Based..

iRadimed Corporation (IRMD) Stock Analysis: Exploring a 22.12% Upside Potential in the Healthcare Sector

iRadimed Corporation (NASDAQ: IRMD), a key player in the medical devices industry, is making waves with its promising potential upside of 22.12%. As it stands, the..

GH Research PLC (GHRS) Stock Analysis: Unveiling a 185.60% Upside Potential for Biotech Investors

GH Research PLC (NASDAQ: GHRS) is making waves in the biotechnology sector with its promising pipeline of depression treatments and an impressive potential upside of 185.60%...

Niagen Bioscience (NAGE) Stock Analysis: A Promising Biotech with 8.32% Upside Potential

Niagen Bioscience, Inc. (NASDAQ: NAGE), a burgeoning name in the biotechnology sector, presents a compelling narrative for investors seeking exposure to the healthcare industry’s innovative edge...

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Exploring a 245% Potential Upside in Biotech Innovation

Bicara Therapeutics Inc. (NASDAQ: BCAX) is capturing investor attention with its striking potential upside of 245.34%, as reflected by its average target price of $32.60 against..

Pharming Group N.V. (PHAR) Stock Analysis: A Biotech Gem with 186% Upside Potential

Pharming Group N.V. (PHAR), a prominent player in the biotechnology sector, is capturing investor attention with its impressive potential for upside. With a current market capitalization..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Exploring a 224.95% Potential Upside in Biotech

For investors eyeing the healthcare sector, particularly the dynamic field of biotechnology, Trevi Therapeutics, Inc. (NASDAQ: TRVI) presents an intriguing opportunity. With a market capitalization of..

Praxis Precision Medicines (PRAX) Stock Analysis: A 154% Potential Upside with Analyst Confidence

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a cutting-edge player in the biotechnology sector, is capturing investor attention with its promising clinical advancements and a remarkable 154%..

CareDx, Inc. (CDNA) Stock Analysis: Exploring a 76.85% Potential Upside in the Diagnostics Sector

For investors keen on tapping into the healthcare sector’s diagnostics and research industry, CareDx, Inc. (NASDAQ: CDNA) offers an intriguing proposition. With its focus on developing..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: A Biotech Gem with 111% Potential Upside

Investors seeking promising opportunities in the biotechnology sector might find Gyre Therapeutics, Inc. (NASDAQ: GYRE) an intriguing prospect. With its focus on developing innovative small-molecule drugs..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds